Home    Back

Adjuvant without active component    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease2
17Multiple system atrophy1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02758730
(ClinicalTrials.gov)		November 201526/4/2016Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA PatientsA Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBAParkinson's DiseaseBiological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active componentAffiris AGUniversity Hospital TuebingenWithdrawn40 Years80 YearsBoth0Phase 1Germany
2NCT02267434
(ClinicalTrials.gov)		December 20144/9/2014Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's DiseaseA Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesBiological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active componentAffiris AGPROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum JuelichCompleted45 Years70 YearsBoth36Phase 1Austria

17. Multiple system atrophy    [ 107 clinical trials,   153 drugs,   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways]
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02270489
(ClinicalTrials.gov)		December 11, 20144/9/2014Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSAA Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System AtrophyMultiple System Atrophy;Neurodegenerative DiseasesBiological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active componentAffiris AGUniversity Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Forschungszentrum Juelich;University Hospital, ToulouseCompleted30 Years75 YearsAll30Phase 1France